Company Overview and News

 
JSW gets 90% lenders backing to bid for Bhushan Power and Steel

2h freepressjournal.in
New Delhi : JSW Steel’s Rs 19,700 crore offer for debt-laden Bhushan Power and Steel (BPSL) has been backed by around 90 per cent of lenders, a source in the know of the matter said. Besides JSW Steel, Tata Steel and Liberty House have also submitted bids for the stressed steel company. The voting on offers had begun on Monday and ended Wednesday, the person said. Till Tuesday, the offer submitted by JSW Steel had received over 66 per cent of votes of the members of the committee of creditors (CoC)
500470 TTST TATASTEEL TATLY 500228 BHUSANSTL JSWSTEEL 500055

 
Its advantage JSW in a three-cornered fight for Bhushan Power and Steel

18h financialexpress
Lenders to the bankrupt Bhushan Power and Steel are understood to have backed the revised offer of Sajjan Jindal-led JSW Steel, which means that rival Tata Steel and UK’s Liberty House have lost out in the race to acquire the firm.
ESL AMKD 500228 BHUSANSTL 532727 AMTEKAUTO 533264 JSWSTEEL 500470 TTST PNJZY TATASTEEL 532461 TATLY ADHUNIK PNB 520077 500055

 
JSW may not pursue Essar Steel if it wins Bhushan Power

20h livemint
Mumbai: JSW Steel Ltd may not pursue its interest in buying out bankrupt Essar Steel if it wins the stressed Bhushan Power and Steel Ltd instead, said two people close to the development. According to a few members of Bhushan Power and Steel’s committee of creditors (CoC) that Mint spoke to, bankers are overwhelmingly in favour of JSW Steel’s offer for the stressed plant.
500470 TTST TATASTEEL TATLY 500228 BHUSANSTL 513216 JSWSTEEL 500055 UTTAMSTL

5
Sensex logs first fall in 4 days, tanks 383 pts on rupee woes

2018-10-17 freepressjournal.in
Mumbai: The BSE benchmark Sensex snapped its three-day gains, plunging 383 points due to heavy selling mainly in financial and auto stocks as rising crude prices and rupee volatility spooked investors. The flagship index swung nearly 880 points both ways on alternate bouts of buying and selling during the session. The NSE Nifty too fell by 131.70 points to slip below 10,500-mark. Intense selling pressure was witnessed in select counters led by auto, realty and oil&gas stocks.
BAJAJ-AUTO 500325 RELIANCE 532977 BHRQY 533278 532215 535789 500470 532187 AXISBANK RIGD HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY RLNIY YESBANK AXB INDUSINDBK 511072 IBN IDKQY 535322 532648 YYBKY VEDL REPCOHOME AXBKY 500182 IBULHSGFIN 532454 AXBA DHFL ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA TTM

 
Bhushan Power lenders are said to back JSW’s $2.7 billion offer

2018-10-17 livemint
Mumbai: Creditors of Bhushan Power & Steel Ltd, a major debt-laden Indian mill, are poised to name JSW Steel Ltd as the preferred bidder in a sale seen as a key test of the country’s new bankruptcy law, people familiar with the matter said.
500470 TTST TATASTEEL TATLY 500228 JSWSTEEL

 
Indian Institute of Foreign Trade summer placement ends, students grab average Rs 1.48-lakh stipend from Swiggy, Microsoft, others

2018-10-17 financialexpress
The Indian Institute of Foreign Trade (IIFT) recently concluded its summer placement for the 2018-20 batch with students securing an average stipend of Rs 1.48 lakh per annum. The institute is set up under the Ministry of Commerce and it conducts two rounds of placement each year. According to a statement released by IIT, the summer placements for the batch that will pass out in 2020, witnessed the participation of a large number of companies from different sectors and industries.
YESBANK AXB 500877 APOLLOTYRE 532648 YYBKY AYRQY 532215 AXBKY AXBA 500470 PIDILITIND TTST TATASTEEL TATLY PDLTY AXISBANK 500331

 
IBC case: JSW Steel emerges front-runner for bankrupt Bhushan Power and Steel; here’s what you need to know

2018-10-16 financialexpress
JSW Steel, with its revised offer of Rs 19,700 crore for bankrupt Bhushan Power and Steel (BPSL), has emerged as the front-runner by getting 66.6% lenders’ votes in its favour, ET Now and CNBC-TV18 reported citing unidentified sources.
500470 TTST TATASTEEL TATLY 500228 BHUSANSTL JSWSTEEL 500055

 
JSW Steel takes the lead in Bhushan Power Steel race

2018-10-16 moneycontrol
JSW Steel has taken a lead in the Bhushan Power & Steel race, with its bid garnering 66.6 percent of the lenders' vote.
500470 TTST TATASTEEL TATLY 500228 JSWSTEEL

4
Sensex reclaims 35K-mark; rises over 200 points on earnings optimism     

2018-10-16 freepressjournal.in
Mumbai: The benchmark BSE Sensex gained almost 219 points to reclaim the 35,000-mark in early trade Tuesday as investors widened their positions ahead of quarterly earnings from some bluechip companies amid positive Asian cues.
BAJAJ-AUTO 532977 BHRQY 500470 532187 HEROMOTOCO 500570 BHARTIARTL TATAMOTORS YESBANK ALNSE INDUSINDBK IBN 532648 YYBKY VEDL 500182 532454 ICICIBANK TTST TATASTEEL TATLY 532174 HRTQY TTM

33
EU mergers and takeovers (Oct 15)

2018-10-15 reuters
BRUSSELS, Oct 15 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY DTEGF WHR 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA

 
5th NPA resolution soon: Who will win bankrupt Bhushan Power and Steel? Here’s list of biggies locked in race

2018-10-15 financialexpress
Bhushan Power and Steel (BPSL) might become the fifth non-performing asset (NPA) account to get resolved under the Insolvency and Bankruptcy Code (IBC) from the Dirty Dozen list as its lenders are likely to take a decision on the bids on Monday. The Committee of Creditors (CoC) of BPSL on Monday is expected to decide on the revised bid submitted by JSW Steel for buying-out the bankrupt company.
500470 TTST TATASTEEL TATLY 500228 BHUSANSTL JSWSTEEL 500055

 
Lenders to vote on offers for Bhushan Power Steel

2018-10-15 moneycontrol
After a lull of over two months, lenders of Bhushan Power & Steel will vote on bids for the stressed company.
500470 TTST TATASTEEL TATLY 500228 JSWSTEEL

 
Moody#39;s rating change of Thyssenkrupp a concern for Tata Steel JV

2018-10-15 moneycontrol
The recent rating change of Thyssenkrupp by Moody’s, after the German conglomerate split its business, is not a heartening one for its joint venture with Tata Steel.
500470 TTST TATASTEEL TATLY

 
Tata Sponge Q2 review: Profitability to improve, valuations remain attractive

2018-10-15 moneycontrol
Tata Sponge continues to see better earnings on higher sponge prices, which in turn was led by strong industry demand. Realisations in Q2 FY19 was close to Rs 22,000 per tonne against average realisations of Rs 21,500\t earned in the preceding quarter. This along with the marginal improvement in volumes led to an increase in sales. The latter grew 29 percent year-on-year to Rs 216.2 crore.
500470 TTST TATASTEEL TATLY

1
Sensex slips 71 points on negative economic data, weak rupee

2018-10-15 freepressjournal.in - 1
Mumbai: The BSE benchmark Sensex after reclaiming the 35,000-mark fell 71 points to quote at 34,662.73 Monday, as the IIP slipped to a three-month low in August and retail inflation rose marginally in September. Besides, weak Asian cues on worries over China-Us trade dispute influenced sentiment.
BAJAJ-AUTO ALNSE AXB IBN HINDUNILVR 532977 BHRQY 533278 VEDL 532215 AXBKY 532454 AXBA ICICIBANK 500470 TTST TATASTEEL TATLY AXISBANK 532174 500696 BHARTIARTL CLNDY COALINDIA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...